Dr. Oliver Rausch is a veteran drug-discovery scientist with a deep background in biochemistry, cell biology, and translational research. He holds a PhD from the Institute of Cancer Research (London) and has led research and development efforts across several major pharmaceutical and biotech organizations, including leadership roles at Cellzome (now part of GSK), UCB Pharma, and as Programme Director for the National Institute for Health Research (NIHR) in the UK. Formerly Chief Scientific Officer of STORM Therapeutics, he oversaw the development of its target-discovery platform and led efforts to bring small-molecule drug candidates — particularly those targeting RNA-modifying enzymes — from discovery through to the clinic.

This extensive experience positions Oliver as a valuable asset to AMPLY Discovery. Given AMPLY’s mission to harness evolutionary and AI-driven approaches to uncover novel natural-product-derived medicines, Oliver’s track record in early-stage drug discovery, translational biology, and guiding molecules into development could help shape and execute robust discovery pipelines. He will contribute to target-selection strategy, design of screening assays, optimizing lead-compound development, and ultimately help translate AMPLY’s AI-identified candidates into therapeutic leads with real clinical potential — bridging the gap between computational discovery and drug development.